Optimi Health plans Phase III trial of PTSD therapy

Optimi Health is set to initiate a Phase III clinical trial to assess MDMA-assisted therapy to treat individuals living with PTSD in Canada. Participants will receive synthetic MDMA hydrochloride during two sessions, spaced weeks apart along with psychotherapy. PTSD can occur after experiencing or witnessing traumatic or life-threatening events. Credit: Phalexaviles / Shutterstock.com. Optimi Health is set to initiate a Phase III clinical trial to assess methylenedioxymethamphetamine (MDMA)-assisted therapy to treat individuals living with post-traumatic stress disorder (PTSD) in Canada. The Health Canada-authorised trial is planned to start next year and will enrol up to 100 participants at sites across…

Source: Clinical Trials Arena